FDA Panel Recommends Six of Seven Peptides for Compounding, Rejects Emideltide
The FDA’s Pharmacy Compounding Advisory Committee closed its two-day meeting on July 24 having recommended six of the seven peptides under review for the Section 503A Bulk Drug Substances List. Only emideltide, also known as DSIP, failed to pass, falling 6 to 7 with one abstention.
On July 23, the committee voted 8 to 6, with one abstention, to add both the free base and acetate forms of BPC-157. KPV and TB-500 each passed by the same 8 to 6 margin, with one abstention apiece. MOTS-c passed 7 to 5, with two abstentions. On July 24, epitalon passed 7 to 4 for insomnia, and semax passed 8 to 5 for migraines, cerebral ischemia, and trigeminal neuralgia. Every recommendation went directly against FDA career staff, who had concluded in briefing documents that none of the seven compounds met the four factor evaluation standard under 21 CFR 216.23(c). All seven substances were pulled into legal limbo in 2023, when the FDA barred compounding pharmacies from dispensing them over stated safety concerns.
Background
The 503A Bulks List determines which active ingredients a compounding pharmacy may legally use to prepare a patient-specific prescription. A peptide left off the list exists in a gray zone. It is not FDA-approved as a drug, and compounding pharmacies cannot legally prepare it either, which has pushed demand toward unregulated overseas suppliers. The Industry Pulse hub has tracked this list closely since April, when FDA reopened these seven compounds for review at the direction of HHS Secretary Robert F. Kennedy Jr.
A Committee Divided Along Financial Lines
Several of the panel’s yes votes came from members who advise or work for telehealth companies positioned to benefit from wider peptide access, according to reporting from STAT and Time. Dr. Haleem Mohammed, chief medical officer of telehealth firm Gameday Men’s Health, voted yes across the board, framing the choice as harm reduction against the gray market rather than an endorsement of clinical evidence. Opposing voices on the committee, including Dr. Elizabeth Rebello of MD Anderson Cancer Center, argued the votes reflected market demand rather than science.
FDA staff had flagged that the only available trial data on BPC-157 for ulcerative colitis came from a small abstract involving 46 patients using an enema formulation, not an injectable. None of the KPV studies staff reviewed were conducted in humans, and staff briefing documents raised similar evidence gaps across the remaining compounds.
Why Emideltide Was Different
FDA staff opposed all seven peptides on the same grounds going into the meeting. Emideltide stood apart in how the panel itself responded. David Pope, chief pharmacy officer at XiFin Pharmacy Solutions, had voted with the majority on the four peptides reviewed Thursday, then joined the dissenters against emideltide, citing what he described as potentially dangerous downstream consequences tied to its proposed use for opioid withdrawal, chronic insomnia, and narcolepsy. That specific safety concern, distinct from the general evidence gap FDA staff raised for every compound, appears to be what tipped the vote.
What the Votes Do Not Do
A PCAC recommendation is not binding. The FDA must still run each compound through a public rulemaking process before any change to the 503A list takes effect, a process that typically runs eight to twenty four months, and the agency has departed from committee recommendations before. Mary Thanh Hai, director of the Office of New Drugs, noted that once a substance reaches the 503A list, FDA has no authority to require compounders to submit safety or efficacy data going forward. Analysts have nonetheless pointed to the financial stakes driving interest in the outcome. Hims & Hers shares rose more than 10 percent following the BPC-157 vote, and one estimate cited in Time put the addressable telehealth opportunity across all seven peptides at roughly 2.2 billion dollars if the full slate clears.
Implications for Research Peptide Buyers
This closes the PCAC’s first pass at all seven peptides, but not the underlying question. Six compounds now move toward a lengthy rulemaking process, and emideltide’s rejection does not remove it from further FDA review, it simply means compounding pharmacies gained no new legal pathway for it this week. For laboratories and researchers currently sourcing BPC-157 for research use, nothing about sourcing requirements or documentation standards changes today. What does change is the direction of regulatory attention: a formal rulemaking docket is now forming around most of these compounds, which typically brings more scrutiny of supply chain quality and testing, not less, as the process moves forward.
FDA Panel Recommends Six of Seven Peptides for Compounding, Rejects Emideltide
FDA Panel Recommends Six of Seven Peptides for Compounding, Rejects Emideltide
The FDA’s Pharmacy Compounding Advisory Committee closed its two-day meeting on July 24 having recommended six of the seven peptides under review for the Section 503A Bulk Drug Substances List. Only emideltide, also known as DSIP, failed to pass, falling 6 to 7 with one abstention.
On July 23, the committee voted 8 to 6, with one abstention, to add both the free base and acetate forms of BPC-157. KPV and TB-500 each passed by the same 8 to 6 margin, with one abstention apiece. MOTS-c passed 7 to 5, with two abstentions. On July 24, epitalon passed 7 to 4 for insomnia, and semax passed 8 to 5 for migraines, cerebral ischemia, and trigeminal neuralgia. Every recommendation went directly against FDA career staff, who had concluded in briefing documents that none of the seven compounds met the four factor evaluation standard under 21 CFR 216.23(c). All seven substances were pulled into legal limbo in 2023, when the FDA barred compounding pharmacies from dispensing them over stated safety concerns.
Background
The 503A Bulks List determines which active ingredients a compounding pharmacy may legally use to prepare a patient-specific prescription. A peptide left off the list exists in a gray zone. It is not FDA-approved as a drug, and compounding pharmacies cannot legally prepare it either, which has pushed demand toward unregulated overseas suppliers. The Industry Pulse hub has tracked this list closely since April, when FDA reopened these seven compounds for review at the direction of HHS Secretary Robert F. Kennedy Jr.
A Committee Divided Along Financial Lines
Several of the panel’s yes votes came from members who advise or work for telehealth companies positioned to benefit from wider peptide access, according to reporting from STAT and Time. Dr. Haleem Mohammed, chief medical officer of telehealth firm Gameday Men’s Health, voted yes across the board, framing the choice as harm reduction against the gray market rather than an endorsement of clinical evidence. Opposing voices on the committee, including Dr. Elizabeth Rebello of MD Anderson Cancer Center, argued the votes reflected market demand rather than science.
FDA staff had flagged that the only available trial data on BPC-157 for ulcerative colitis came from a small abstract involving 46 patients using an enema formulation, not an injectable. None of the KPV studies staff reviewed were conducted in humans, and staff briefing documents raised similar evidence gaps across the remaining compounds.
Why Emideltide Was Different
FDA staff opposed all seven peptides on the same grounds going into the meeting. Emideltide stood apart in how the panel itself responded. David Pope, chief pharmacy officer at XiFin Pharmacy Solutions, had voted with the majority on the four peptides reviewed Thursday, then joined the dissenters against emideltide, citing what he described as potentially dangerous downstream consequences tied to its proposed use for opioid withdrawal, chronic insomnia, and narcolepsy. That specific safety concern, distinct from the general evidence gap FDA staff raised for every compound, appears to be what tipped the vote.
What the Votes Do Not Do
A PCAC recommendation is not binding. The FDA must still run each compound through a public rulemaking process before any change to the 503A list takes effect, a process that typically runs eight to twenty four months, and the agency has departed from committee recommendations before. Mary Thanh Hai, director of the Office of New Drugs, noted that once a substance reaches the 503A list, FDA has no authority to require compounders to submit safety or efficacy data going forward. Analysts have nonetheless pointed to the financial stakes driving interest in the outcome. Hims & Hers shares rose more than 10 percent following the BPC-157 vote, and one estimate cited in Time put the addressable telehealth opportunity across all seven peptides at roughly 2.2 billion dollars if the full slate clears.
Implications for Research Peptide Buyers
This closes the PCAC’s first pass at all seven peptides, but not the underlying question. Six compounds now move toward a lengthy rulemaking process, and emideltide’s rejection does not remove it from further FDA review, it simply means compounding pharmacies gained no new legal pathway for it this week. For laboratories and researchers currently sourcing BPC-157 for research use, nothing about sourcing requirements or documentation standards changes today. What does change is the direction of regulatory attention: a formal rulemaking docket is now forming around most of these compounds, which typically brings more scrutiny of supply chain quality and testing, not less, as the process moves forward.